Price
No data yet.
Social Signal Score
Analyst Ratings
16 analystsRevenue
$93.53M+366.46%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Warren Foust
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 921
- Beta
- 1.22
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 7.27
Financials
Revenue
$93.53M+366.5%Net Income
$8.06MEBITDA
$13.41MFree Cash Flow
$19.20M+2991.1%EPS (diluted)
$0.16Shares Outstanding (diluted)
51.50M+27.2%Operating Expenses
$59.63MCash & Debt
$181.49MReturn of Capital
$2.74MRevenue by Segment (annual)
$313.90MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $239.44M | $-80.45M | $-1.62 |
| 2024 | $313.90M | $-20.21M | $-0.41 |
| 2023 | $322.42M | $21.35M | $0.44 |
| 2022 | $284.39M | $39.66M | $0.83 |
| 2021 | $230.47M | $27.51M | $0.52 |
| 2020 | $163.46M | $5.91M | $0.13 |
| 2019 | $150.19M | $14.05M | $0.32 |
| 2018 | $123.95M | $4.97M | $0.11 |
| 2017 | $90.61M | $-2.14M | $-0.05 |
| 2016 | $82.43M | $-12.13M | $-0.30 |
| 2015 | $77.12M | $-6.53M | $-0.17 |
| 2014 | $74.99M | $-8.39M | $-0.22 |
| 2013 | $72.22M | $398.0K | $0.01 |
| 2012 | $63.78M | $-1.76M | $-0.05 |
Valuation
STAAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-57.14%Social Signal Score
Mentions (7)
- Newsfool.com·6d ago·Positive
Why Staar Surgical Zoomed Almost 8% Higher on Tuesday That pundit now believes it's a buy. He cited positive sales momentum, especially in a key market overseas.
View source ↗ - Newsfool.com·10d ago·Neutral
Why Staar Surgical Stock Soared Today It anticipates this will run for one year. The company's recent fundamentals have been rather impressive.
View source ↗ - Newsgurufocus.com·12d ago·Positive
Is Staar Surgical Co (STAA) a Bargain After 4.1% Drop? GF Value Says Undervalued On September 23, 2026, Staar Surgical Co (STAA) shares fell by 4.1%, closing at $19.80. The stock has had a turbulent year, trading within a 52-week range of $1
View source ↗ - Newszacks.com·49d ago·Negative
Deciphering Staar Surgical (STAA) International Revenue Trends Review Staar Surgical's (STAA) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
View source ↗ - Newsmarketbeat.com·54d ago·Positive
STAAR Surgical Q2 Earnings Call Highlights STAAR Surgical NASDAQ: STAA reported second-quarter 2026 net sales of $93.5 million, up 111% from $44.3 million a year earlier, as growth in China, the Americas and parts of Europe contributed to what President and Chief Executive Officer Warren Foust called the company's strongest first half of revenue performance.
View source ↗ - Newsseekingalpha.com·54d ago·Positive
STAAR Surgical Company (STAA) Q2 2026 Earnings Call Transcript STAAR Surgical Company (STAA) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·54d ago·Neutral
Staar Surgical (STAA) Surpasses Q2 Earnings and Revenue Estimates Staar Surgical (STAA) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to a loss of $0.07 per share a year ago.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $0.05 per share
Typical surprise +11.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$0.16 vs $0.22miss
- Wed, May 13$0.38 vs $0.05beat
- Tue, Mar 3$-0.20 vs $0.18miss
- Wed, Nov 5$0.46 vs $0.18beat
- Wed, Aug 6$-0.34 vs $-0.56beat
- Wed, May 7$-0.52 vs $-0.59beat
Estimates and results for STAA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by STAA officers and directors.
- Bought
- $11.3m
- Sold
- —
2 trades
0 trades
- Broadwood Partners, L.p.bought
- Broadwood Partners, L.p.bought
97 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in STAA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.